Abstract
ABO blood group polymorphisms are determined by A, B, or H antigens. H substance is a precursor converted into A or B antigens; its presence is characteristic of blood group O. This study explores the enzymatic modification of H antigens on human erythrocytes using $\alpha$-1,2-L-fucosidase and N-acetylgalactosaminyltransferase (A-transferase) to create "Enzyme-Converted group O Red Blood Cells" (ECO-RBC). While Type 2 H chains were successfully modified, Type 3 chains showed resistance, likely due to steric hindrance.
Introduction
Blood transfusions require precise ABO matching. The H antigen is the core precursor for A and B antigens. Individuals with the rare "Bombay" phenotype lack the H antigen entirely and produce anti-H antibodies, making them incompatible with standard type O blood. This research investigates the feasibility of using enzymes to "strip" or modify H antigens on red blood cells (erythrocytes) to mimic the Bombay phenotype or create universal donor units. Specifically, the study examines how different structural "flavors" of the H antigen—Type 2 and Type 3 chains—respond to enzymatic treatment.
Methods
Red blood cells from healthy donors (A1, A2, B, and O) were sourced from the Shanghai Blood Centre, with Para-Bombay cells serving as a critical negative control. Two enzymatic strategies were employed:
- Cleaving: $\alpha$-1,2-L-fucosidase was used to remove the terminal L-fucose residue from the H antigen. Optimal conditions were tested across a pH range of 5.6 to 6.9 and incubation times of 1 to 4 hours.
- Transferring: Plasma-derived A-transferase was used to attempt the conversion of H antigens into A antigens, specifically targeting Type 3 chains.
Verification was performed using Flow Cytometry (FACS) with monoclonal antibodies like MBr1 and DG gel neutral analysis for antigen detection. Cellular integrity was assessed via Scanning Electron Microscopy (SEM) and membrane potential measurements.
Results
pH and Time Sensitivity
The $\alpha$-1,2-L-fucosidase enzyme exhibited maximum activity at an acidic pH (5.6–6.0). As shown in Figure 1, the enzyme's efficiency in stripping fucose decreased significantly as the environment became more neutral (pH 6.9). Complete removal of Type 2 H antigens from A1, A2, B, and O cells was achieved after 4 hours of treatment at pH 5.6, resulting in what the authors term "FM-erythrocytes."
Cellular Integrity and Safety
The enzymatic treatment was remarkably specific, leaving other major blood group systems (Rh, MNS, Kell, Duffy, and Kidd) untouched. SEM imaging confirmed that the treated FM-erythrocytes maintained their characteristic biconcave shape (Figure 3). While a slight decrease in absolute membrane potential was observed, this was determined to be a side effect of the acidic buffer rather than the loss of the fucose sugar itself.
Structural Resistance of Type 3 Chains
A critical finding was the resistance of Type 3 H antigens to enzymatic modification. Despite prolonged incubation with A-transferase, Type 3 chains on A1 and A2 cells remained detectable. This resistance is hypothesized to stem from "steric hindrance," where the complex, branched structure of Type 3 chains physically blocks the enzyme's access to the target fucose residue.
Discussion
The study demonstrates the successful enzymatic removal of the predominant Type 2 H antigens, moving closer to the goal of universal donor blood. However, the persistence of Type 3 and Type 4 chains presents a significant hurdle. Because these structures remain intact, the modified cells do not perfectly replicate the Bombay phenotype and might still trigger immune responses in sensitized recipients. Future research must focus on engineering glycosidases capable of overcoming steric hindrance to ensure complete antigen removal. Scaling these laboratory successes into transfusion-ready clinical products remains a major technical and regulatory challenge.
Summary updated